CD5 CAR T-cells: Each subject receive CD5+ T-lymphoma Targeted CAR T-cells by intravenous infusion
Study summary
A Clinical Study on the Safety and Effectiveness of targeting CD5 CAR-T Cells in the treatment of r/r CD5+ T-lymphoma
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* 1\. According to the 2016 WHO classification of lymphocyte tumors, histologically confirmed CD5-positive T-cell non-Hodgkin lymphoma (T-NHL),
R/R T-NHL(meets one of the following conditions) :
1. Subjects did not go into remission or relapse after receiving second-line or more chemotherapy regiments;
2. Primary drug resistance;
3. Relapse after autologous hematopoietic stem cell transplantation;
* 2.CD5 expression rate was \>90%;
* 3\. According to Lugano 2014, there should be at least one evaluable tumor lesion;
* 4\. Total bilirubin ≤51 (mol/L), Alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) ≤ 3 times the upper limit of the normal range, creatinine ≤176.8 (mol/L);
* 5\. Echocardiography showed left ventricular ejection fraction (LVEF) ≥50%;
* 6\. Refers to the pulse oxygen saturation 92% or higher oxygen (state);
* 7\. Estimated life expectancy of minimum of 12 weeks;
* 8\. ECOG 0-2;
* 9\. Pregnant/lactating women, or male or female patients who have fertility and are willing to take effective contraceptive measures at least 6 months after the last cell infusion during the study period;
* 10\. Those who voluntarily participated in this trial and provided informed consent;
Exclusion Criteria:
* 1\. History of epilepsy or other central nervous system disorders;
* 2\. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;
* 3\. Active infection of hepatitis B virus, C virus or hepatitis E virus;
* 4\. Active infected persons who are not cured;
* 5\. Before using any gene therapy products;
* 6\. Received anti-tumor therapy before infusion, should meet the following any one should be ruled out:
1. treated with systemic corticosteroids therapy within 72 hours (except glucocorticoid physiological replacement therapy, such as prednisone \< 10 mg/d or an equivalent dose of the drug);
2. received within 72 hours of small molecule targeted therapy;
3. 2 weeks received systemic chemotherapy except (pretreatment);
4. four weeks received radiotherapy;
* 7\. The proiferation rate is less than 5 times response to CD3/CD28 co-stimulation signal;
* 8\. Any unsuitable to participate in this trial judged by the investigator;
* 9\. Any situation that researchers believe may increase the risk to the subjects or interfere with the trial results.
Primary outcome measure(s)
Dose-limiting toxicity (DLT) — Up to 28 days after Treatment Adverse events assessed according to NCI-CTCAE v5.0 criteria
Incidence of treatment-emergent adverse events (TEAEs) — Up to 2 years after Treatment Incidence of treatment-emergent adverse events \[Safety and Tolerability\]
Trial sites (1)
Facility
City
Region
Status
The first affiliated hospital of medical college of zhejiang university
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.